NARI

ANALYST NOTE: NARI (Inari Medical, Inc.) Date: 2026-06-13 Current Price: $79.97

1. Structural Readiness

State: Context-Only Conservative Entry: — (Awaiting confirmed breakout) Aggressive/Pre-Breakout Entry: — (Not actionable on forming structure alone) Breakout Level: — (Pending confirmation) Current Price: $79.97 Extension: — ATR Current: 0.8% (Sub-threshold volatility) ATR at Breakout: — (Not yet established) Pivot Strength: —

Analysis of Setup:

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led Secular Thesis: None Named

At this date, there is no named macro or secular thesis driving this specific setup. This is a TACTICAL trade driven by the quality of the technical setup and the underlying business fundamentals rather than a broad thematic rotation. The conviction must be derived strictly from the structural integrity of the chart pattern (the forming coil) and the strength of the company's operational execution as reported in recent filings. No external macro narrative is being applied to this analysis.

3. Business Analysis

Company Overview: Inari Medical, Inc. operates in the medical device industry, specifically within the vascular and interventional therapy sector. The company designs, develops, and commercializes mechanical thrombectomy systems for the treatment of venous and arterial thrombotic diseases.

Business Model & Products: The company generates revenue through the sale of its proprietary devices and consumables. Key product lines identified in the evidence base include:

• FlowTriever: A catheter-based aspiration and mechanical thrombectomy system targeting pulmonary embolism (PE).
• ClotTriever: A mechanical thrombectomy solution for extracting clots from major blood vessels, specifically targeting deep vein thrombosis (DVT).
• FlowTriever 2: An enhanced version featuring a new disk design for capturing wall-adherent clots and reducing procedure time.
• FlowSaver / FlowStasis: Large-bore suture retention devices for managing venous access points.

Operational Performance (as of 2026-06-13): The company has demonstrated significant commercial traction and operational maturity.

• Revenue Growth: In Q3 2024 (reported Oct 28, 2024), Global VTE revenue reached $145.3 million, up 19.7% year-over-year. Global Emerging Therapies revenue grew 64% to $8 million in the same period.
• Guidance: Management raised full-year 2024 revenue guidance to a range of $601.5 million to $604.5 million, reflecting 22% to 22.5% growth over 2023.
• Market Penetration: As of Q3 2024, the company had secured approvals in over 50 of the approximately 200 high-volume Limb Salvage Centers of Excellence targeted for early launch.
• Profitability Trajectory: Management stated in Q3 2024 that they are "very confident in delivering on their commitment to sustained GAAP operating profitability in the first half of 2025."

4. Archetype and Conviction

Archetype: Growth Leader Fit Rationale: The name fits the Growth Leader archetype due to its double-digit revenue growth (22%+), successful commercial expansion into new indications (Limb Salvage), and the transition toward sustained operating profitability. The financial spine indicates a clear path to earnings growth, with forward consensus EPS projected at $0.47875 for FY1 and $0.86333 for FY2.

Conviction Stack:

• Thesis Strength: Moderate. The lack of a named secular thesis limits the "narrative" upside, but the tactical setup is clean.
• Evidence Quality: High. The evidence base is robust, citing specific earnings transcripts and financial projections. The guidance raise and profitability commitment are strong fundamental anchors.
• Setup Readiness: Partial. The setup is "Forming," meaning it is a watch-list candidate but not yet a confirmed entry. The price must break above the resistance level to confirm the structure.
• Rerating Potential: High. The transition from growth-at-cost to sustained profitability (expected H1 2025) typically triggers multiple expansion in the medical device sector.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Confirmed Breakout: A daily close above the established resistance level (breakout level) would transition the coil to "Confirmed-Active," validating the setup.
• Profitability Confirmation: Public confirmation that GAAP operating profitability was achieved in H1 2025 as guided.
• Volume Expansion: An increase in ATR and trading volume accompanying a price move above resistance.

What Would Invalidate the Case:

• Guidance Miss: A failure to meet the raised 2024 revenue guidance or a delay in the profitability timeline.

Gaps in Evidence:

• 2026 Financials: While forward consensus is provided, actual 2026 financial results are not yet in the evidence base (as the date is 2026-06-13, we are looking at forward estimates for FY1/FY2 relative to the 2024 base).
• Competitive Landscape: No specific data on competitor actions or market share shifts in 2026 is available in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Raised 2024 revenue guidance to $601.5-$604.5M reflecting 22% growth; Management confidence in sustained GAAP operating profitability in H1 2025; Strong Q3 VTE revenue growth of 19.7% YoY to $145.3M. Key risks: Sub-threshold ATR (0.8%) indicates low volatility and potential for stagnation; Setup is "Forming" and not yet confirmed; Lack of named secular thesis limits narrative tailwinds. Sizing hint: Position size should be conservative until breakout confirmation; treat as a watch-list holding rather than a core position. Expected path: Price consolidates within the forming structure; a breakout above resistance triggers a re-rating as profitability milestones are met. Expected horizon: 3 to 6 months for setup confirmation and thesis validation.